Furthermore, treatment with IL-33 alleviated HFD-induced hepatic steatosis, reduced serum alanine aminotransferase (ALT) levels, and ameliorated insulin resistance and glucose intolerance. The gene discussed is GPT; the disease is fatty liver disease.